Jazz Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 1/6
Jazz Pharmaceuticals has a total shareholder equity of $3.7B and total debt of $5.7B, which brings its debt-to-equity ratio to 153%. Its total assets and total liabilities are $11.4B and $7.7B respectively. Jazz Pharmaceuticals's EBIT is $810.7M making its interest coverage ratio 2.8. It has cash and short-term investments of $1.6B.
Key information
153.0%
Debt to equity ratio
US$5.72b
Debt
Interest coverage ratio | 2.8x |
Cash | US$1.63b |
Equity | US$3.74b |
Total liabilities | US$7.66b |
Total assets | US$11.39b |
Recent financial health updates
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Oct 31Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Jul 12We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt
Apr 12Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Aug 10Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt
May 12Recent updates
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Updated View On Jazz Pharmaceuticals' 2025 Goals
Jan 29Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking
Dec 26Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Oct 31Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Jul 12We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt
Apr 12Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market
Aug 24Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy
Aug 18Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Aug 10Jazz Pharmaceuticals: Strong Launch Of Xywav In Idiopathic Hypersomnia
Jun 08Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt
May 12Jazz Pharmaceuticals: Imminent Danger With A Worrying History
Feb 04Financial Position Analysis
Short Term Liabilities: JAZZ's short term assets ($3.4B) exceed its short term liabilities ($1.5B).
Long Term Liabilities: JAZZ's short term assets ($3.4B) do not cover its long term liabilities ($6.1B).
Debt to Equity History and Analysis
Debt Level: JAZZ's net debt to equity ratio (109.3%) is considered high.
Reducing Debt: JAZZ's debt to equity ratio has increased from 57.9% to 153% over the past 5 years.
Debt Coverage: JAZZ's debt is not well covered by operating cash flow (19.1%).
Interest Coverage: JAZZ's interest payments on its debt are not well covered by EBIT (2.8x coverage).